Merck & Co [MRK] vs Amgen [AMGN] Detailed Stock Comparison
Merck & Co
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Merck & Co wins in 15 metrics, Amgen wins in 5 metrics, with 0 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Merck & Co | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.76 | 22.62 | Merck & Co |
| Price-to-Book Ratio | 4.23 | 20.03 | Merck & Co |
| Debt-to-Equity Ratio | 72.16 | 756.65 | Merck & Co |
| PEG Ratio | -0.72 | 0.25 | Merck & Co |
| EV/EBITDA | 8.25 | 12.20 | Merck & Co |
| Profit Margin (TTM) | 25.79% | 18.96% | Merck & Co |
| Operating Margin (TTM) | 37.47% | 32.73% | Merck & Co |
| EBITDA Margin (TTM) | 37.47% | 32.73% | Merck & Co |
| Return on Equity | 35.42% | 99.14% | Amgen |
| Return on Assets (TTM) | 13.01% | 7.51% | Merck & Co |
| Free Cash Flow (TTM) | $18.10B | $10.39B | Merck & Co |
| Dividend Yield | 3.01% | 4.09% | Amgen |
| 1-Year Return | -28.53% | -16.83% | Amgen |
| Price-to-Sales Ratio (TTM) | 3.25 | 4.26 | Merck & Co |
| Enterprise Value | $233.69B | $196.97B | Merck & Co |
| EV/Revenue Ratio | 3.67 | 5.64 | Merck & Co |
| Gross Profit Margin (TTM) | 77.50% | 67.20% | Merck & Co |
| Revenue per Share (TTM) | $25 | $65 | Amgen |
| Earnings per Share (Diluted) | $6.49 | $12.22 | Amgen |
| Beta (Stock Volatility) | 0.38 | 0.48 | Merck & Co |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Merck & Co vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Merck & Co | -2.75% | -2.24% | 3.13% | 1.21% | -11.29% | -16.50% |
| Amgen | -2.24% | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Merck & Co | -28.53% | -5.60% | 1.14% | 66.49% | 139.06% | 200.47% |
| Amgen | -16.83% | 19.62% | 11.61% | 83.60% | 400.71% | 225.82% |
News Based Sentiment: Merck & Co vs Amgen
Merck & Co
News based Sentiment: MIXED
September was a month of contrasts for Merck, showcasing both promising pipeline developments and challenging operational decisions. While strong earnings and a proactive approach to future growth are positive, the cancellation of the London research hub and declining Gardasil sales introduce uncertainty, resulting in a 'mixed' overall investment story.
Amgen
News based Sentiment: POSITIVE
Amgen demonstrated a strong financial performance in Q2 2025, exceeding earnings and revenue expectations. Coupled with positive clinical trial data and expanded FDA approval for Repatha, the company appears well-positioned for continued growth, despite mixed analyst sentiment and varied institutional investor activity.
Performance & Financial Health Analysis: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $206.84B | $148.80B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 11,664,882 | 2,148,930 |
| 90 Day Avg. Volume | 11,212,274 | 2,112,570 |
| Last Close | $82.81 | $276.39 |
| 52 Week Range | $73.31 - $119.38 | $253.30 - $339.17 |
| % from 52W High | -30.63% | -18.51% |
| All-Time High | $134.63 (Jun 24, 2024) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -38.49% | -20.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.09% |
| Quarterly Earnings Growth | -0.19% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.19% |
| Operating Margin (TTM) | 0.37% | 0.33% |
| Return on Equity (TTM) | 0.35% | 0.99% |
| Debt to Equity (MRQ) | 72.16 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.57 | $13.80 |
| Cash per Share (MRQ) | $3.45 | $14.91 |
| Operating Cash Flow (TTM) | $18.53B | $12.01B |
| Levered Free Cash Flow (TTM) | $15.56B | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.01% | 4.09% |
| Last 12-Month Dividend | $2.39 | $11.64 |
Valuation & Enterprise Metrics Analysis: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.76 | 22.62 |
| Forward P/E | 8.81 | 13.37 |
| PEG Ratio | -0.72 | 0.25 |
| Price to Sales (TTM) | 3.25 | 4.26 |
| Price to Book (MRQ) | 4.23 | 20.03 |
| Market Capitalization | ||
| Market Capitalization | $206.84B | $148.80B |
| Enterprise Value | $233.69B | $196.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.67 | 5.64 |
| Enterprise to EBITDA | 8.25 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 0.38 | 0.48 |
| Book Value per Share (MRQ) | $19.57 | $13.80 |
Financial Statements Comparison: Merck & Co vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Revenue/Sales | $15.81B | $8.15B |
| Cost of Goods Sold | $3.56B | $2.97B |
| Gross Profit | $12.25B | $5.18B |
| Research & Development | $4.05B | $1.49B |
| Operating Income (EBIT) | $5.55B | $1.18B |
| EBITDA | $6.96B | $4.08B |
| Pre-Tax Income | $5.00B | $1.97B |
| Income Tax | $571.00M | $243.00M |
| Net Income (Profit) | $4.43B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Cash & Equivalents | $8.63B | $8.81B |
| Total Current Assets | $35.50B | $26.93B |
| Total Current Liabilities | $25.17B | $23.01B |
| Long-Term Debt | $33.48B | $54.01B |
| Total Shareholders Equity | $48.40B | $6.21B |
| Retained Earnings | $66.10B | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRK | AMGN |
|---|---|---|
| Operating Cash Flow | $6.30B | $1.71B |
| Capital Expenditures | N/A | $-411.00M |
| Free Cash Flow | $1.17B | $980.00M |
| Debt Repayment | $-2.50B | $-2.50B |
| Common Stock Repurchase | $-1.16B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MRK | AMGN |
|---|---|---|
| Shares Short | 23.83M | 11.80M |
| Short Ratio | 1.96 | 5.85 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 11,664,882 | 2,148,930 |
| Average Daily Volume (90 Day) | 11,212,274 | 2,112,570 |
| Shares Outstanding | 2.53B | 537.00M |
| Float Shares | 2.49B | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.81% | 0.84% |
Dividend Analysis & Yield Comparison: Merck & Co vs Amgen
| Metric | MRK | AMGN |
|---|---|---|
| Last 12-Month Dividend | $2.39 | $11.64 |
| Last 12-Month Dividend Yield | 3.01% | 4.09% |
| 3-Year Avg Annual Dividend | $2.77 | $9.51 |
| 3-Year Avg Dividend Yield | 0.71% | 0.80% |
| 3-Year Total Dividends | $8.31 | $28.54 |
| Ex-Dividend Date | Mar 17, 2025 | Aug 22, 2025 |